INR 32.41
(-7.37%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Cash Flow | 33.78 Million | -5.16 Million | 4.16 Million | -3.7 Million | -884.3 Thousand |
Net Income | -4.93 Million | 6.38 Million | 1.97 Million | 1.64 Million | 1.37 Million |
Depreciation & Amortization | 21 Thousand | 11 Thousand | 11 Thousand | 11 Thousand | 11.02 Thousand |
Deferred income taxes | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - |
Change in working capital | 56.2 Million | -10.09 Million | 2.54 Million | -4.95 Million | -2.17 Million |
Other non-cash items | -686 Thousand | -30.4 Thousand | 180.2 Thousand | -556.4 Thousand | -104.42 Thousand |
Investing Cash Flow | -33.64 Million | 4.65 Million | -4.25 Million | 3.9 Million | 1.02 Million |
Investments in PPE | -36 Thousand | - | - | - | - |
Acquisitions | - | - | - | - | - |
Investment purchases | -53.99 Million | -40 Million | -4.25 Million | - | - |
Sales/Maturities of investments | 19.66 Million | 44.65 Million | - | 3.9 Million | - |
Other Investing Activities | -33.6 Million | 4.65 Million | -4.25 Million | 3.9 Million | 1.02 Million |
Financing Cash Flow | - | - | - | - | - |
Debt repayment | - | - | - | - | - |
Dividends payments | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - |
Other Financing Activities | - | - | - | - | - |
Accounts receivables | 7.74 Million | -8.16 Million | 3.9 Million | -2.88 Million | -1.01 Million |
Accounts payables | - | - | - | - | - |
Inventory | - | - | - | - | 826.57 Thousand |
Other working capital | 48.46 Million | -1.93 Million | -1.35 Million | -2.06 Million | -1.98 Million |
Cash at beginning of period | 2.73 Million | 3.24 Million | 3.32 Million | 3.13 Million | 2.98 Million |
Cash at end of period | 2.87 Million | 2.73 Million | 3.24 Million | 3.32 Million | 3.13 Million |
Capital Expenditure | -36 Thousand | - | - | - | - |
Effect of forex changes on cash | - | - | - | - | - |
Net cash flow / Change in cash | 141 Thousand | -507.8 Thousand | -84.4 Thousand | 197.7 Thousand | 145.36 Thousand |
Free Cash Flow | 33.74 Million | -5.16 Million | 4.16 Million | -3.7 Million | -884.3 Thousand |
Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 17.46 Million | -15.79 Million | -4.93 Million | 5.97 Million | 5.36 Million | 1.46 Million |
Depreciation & Amortization | - | - | 21 Thousand | - | - | - |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | - | - | 56.2 Million | - | - | - |
Other non-cash items | -17.46 Million | 15.79 Million | -686 Thousand | -5.97 Million | -5.36 Million | -1.46 Million |
Investing Cash Flow | - | - | -33.64 Million | - | - | - |
Investments in PPE | - | - | -36 Thousand | - | - | - |
Acquisitions | - | - | - | - | - | - |
Investment purchases | - | - | -53.99 Million | - | - | - |
Sales/Maturities of investments | - | - | 19.66 Million | - | - | - |
Other Investing Activities | - | - | -33.6 Million | - | - | - |
Financing Cash Flow | - | - | - | - | - | - |
Debt repayment | - | - | - | - | - | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | - | - | - | - | - | - |
Accounts receivables | - | - | 7.74 Million | - | - | - |
Accounts payables | - | - | - | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | - | - | 48.46 Million | - | - | - |
Cash at beginning of period | - | - | 2.73 Million | - | - | - |
Cash at end of period | - | - | 2.87 Million | - | - | - |
Capital Expenditure | - | - | -36 Thousand | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | - | 141 Thousand | - | - | - |
Free Cash Flow | - | - | 33.74 Million | - | - | - |
002989
4848
BIOGEN
EGTYF
2119
CGLO